Literature DB >> 24062211

DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA.

Md Mizanur Rahman1, Jyothi Maria Veigas, Paul J Williams, Gabriel Fernandes.   

Abstract

Breast cancer patients often develop bone metastasis evidenced by osteolytic lesions, leading to severe pain and bone fracture. Attenuation of breast cancer metastasis to bone and associated osteolysis by fish oil, rich in EPA and DHA, has been demonstrated previously. However, it was not known whether EPA and DHA differentially or similarly affect breast cancer bone metastasis and associated osteolysis. In vitro culture of parental and luciferase gene encoded MDA-MB-231 human breast cancer cell lines treated with EPA and DHA revealed that DHA inhibits proliferation and invasion of breast cancer cells more potently than EPA. Intra-cardiac injection of parental and luciferase gene encoded MDA-MB-231 cells to athymic NCr nu/nu mice demonstrated that DHA-treated mice had significantly less breast cancer cell burden in bone, and also significantly less osteolytic lesions than EPA-treated mice. In vivo cell migration assay as measured by luciferase intensity revealed that DHA attenuated cell migration specifically to the bone. Moreover, the DHA-treated group showed reduced levels of CD44 and TRAP positive area in bone compared to EPA-treated group. Breast cancer cell burden and osteolytic lesions were also examined in intra-tibially breast cancer cell injected mice and found less breast cancer cell growth and associated osteolysis in DHA-treated mice as compared to EPA-treated mice. Finally, doxorubicin-resistant MCF-7 (MCF-7dox) human breast cancer cell line was used to examine if DHA can improve sensitization of MCF-7dox cells to doxorubicin. DHA improved the inhibitory effect of doxorubicin on proliferation and invasion of MCF-7dox cells. Interestingly, drug resistance gene P-gp was also down-regulated in DHA plus doxorubicin-treated cells. In conclusion, DHA attenuates breast cancer bone metastasis and associated osteolysis more potently than EPA, possibly by inhibiting migration of breast cancer cell to the bone as well as by inhibiting osteoclastic bone resorption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24062211      PMCID: PMC3839302          DOI: 10.1007/s10549-013-2703-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  62 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Docosahexaenoic acid affects cell signaling by altering lipid rafts.

Authors:  William Stillwell; Saame Raza Shaikh; Mustafa Zerouga; Rafat Siddiqui; Stephen R Wassall
Journal:  Reprod Nutr Dev       Date:  2005 Sep-Oct

3.  The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro.

Authors:  Jizhong Yuan; Masako Akiyama; Ken-ichi Nakahama; Takahiro Sato; Hiroshi Uematsu; Ikuo Morita
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-04-13       Impact factor: 3.072

4.  Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE2 biosynthesis, tissue IGF-I levels, and bone morphometry in chicks.

Authors:  B A Watkins; C L Shen; K G Allen; M F Seifert
Journal:  J Bone Miner Res       Date:  1996-09       Impact factor: 6.741

Review 5.  Long-chain polyunsaturated fatty acids: selected mechanisms of action on bone.

Authors:  M C Kruger; M Coetzee; M Haag; H Weiler
Journal:  Prog Lipid Res       Date:  2010-06-17       Impact factor: 16.195

6.  Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells.

Authors:  Patricia D Schley; Humberto B Jijon; Lindsay E Robinson; Catherine J Field
Journal:  Breast Cancer Res Treat       Date:  2005-07       Impact factor: 4.872

7.  Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells.

Authors:  Melanie Baumgartner; Sanda Sturlan; Erich Roth; Barbara Wessner; Thomas Bachleitner-Hofmann
Journal:  Int J Cancer       Date:  2004-11-20       Impact factor: 7.396

8.  Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells.

Authors:  J H Zhang; J Wang; J Tang; B Barnett; J Dickson; N Hahsimoto; P Williams; W Ma; W Zheng; T Yoneda; S Pageau; J Chen
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

9.  Specific effects of gamma-linolenic, eicosapentaenoic, and docosahexaenoic ethyl esters on bone post-ovariectomy in rats.

Authors:  R C Poulsen; E C Firth; C W Rogers; P J Moughan; M C Kruger
Journal:  Calcif Tissue Int       Date:  2007-11-17       Impact factor: 4.333

10.  The impact of omega-3 fatty acids on osteoporosis.

Authors:  M Maggio; A Artoni; F Lauretani; L Borghi; A Nouvenne; G Valenti; G P Ceda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more
  26 in total

1.  Nox2 Activity Is Required in Obesity-Mediated Alteration of Bone Remodeling.

Authors:  Md Mizanur Rahman; Amina El Jamali; Ganesh V Halade; Allal Ouhtit; Haissam Abou-Saleh; Gianfranco Pintus
Journal:  Oxid Med Cell Longev       Date:  2018-11-08       Impact factor: 6.543

2.  Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancer.

Authors:  Lindsay West; Yajie Yin; Stuart R Pierce; Ziwei Fang; Yali Fan; Wenchuan Sun; Katherine Tucker; Allison Staley; Chunxiao Zhou; Victoria Bae-Jump
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Inhibition of PC3 human prostate cancer cell proliferation, invasion and migration by eicosapentaenoic acid and docosahexaenoic acid.

Authors:  Keiichi Oono; Katsuya Takahashi; Saeka Sukehara; Hirohito Kurosawa; Tomio Matsumura; Shun'Ichiro Taniguchi; Shoichiro Ohta
Journal:  Mol Clin Oncol       Date:  2017-06-08

4.  Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.

Authors:  Saraswoti Khadge; Geoffrey M Thiele; John Graham Sharp; Timothy R McGuire; Lynell W Klassen; Paul N Black; Concetta C DiRusso; Leah Cook; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2018-10-16       Impact factor: 5.150

5.  Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells.

Authors:  Thomas J Pogash; Karam El-Bayoumy; Shantu Amin; Krishne Gowda; Ricardo López de Cicco; Maria Barton; Yanrong Su; Irma H Russo; Julie A Himmelberger; Michael Slifker; Andrea Manni; Jose Russo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-11-21       Impact factor: 2.416

6.  Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies.

Authors:  Chiara Cugno; Dhanya Kizhakayil; Rita Calzone; Shaikh Mizanoor Rahman; Ganesh V Halade; Md M Rahman
Journal:  Sci Rep       Date:  2021-05-14       Impact factor: 4.379

Review 7.  The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer.

Authors:  Jiajie Liu; David W L Ma
Journal:  Nutrients       Date:  2014-11-18       Impact factor: 5.717

8.  Targeting Intracellular Cholesterol is a Novel Therapeutic Strategy for Cancer Treatment.

Authors:  Chandi C Mandal; Md Mizanur Rahman
Journal:  J Cancer Sci Ther       Date:  2014-12-20

Review 9.  Suppression of NADPH Oxidase Activity May Slow the Expansion of Osteolytic Bone Metastases.

Authors:  Mark F McCarty; James DiNicolantonio
Journal:  Healthcare (Basel)       Date:  2016-08-25

10.  Docosahexaenoic acid suppresses breast cancer cell metastasis by targeting matrix-metalloproteinases.

Authors:  Eun-Jin Yun; Kyung-Sub Song; Soyeon Shin; Soyeon Kim; Jun-Young Heo; Gi-Ryang Kweon; Tong Wu; Jong-Il Park; Kyu Lim
Journal:  Oncotarget       Date:  2016-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.